实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (5): 781-784.doi: 10.3969/j.issn.1672-5069.2026.05.036

• 胆管癌 • 上一篇    下一篇

CT与MRI增强扫描诊断胆管癌临床分期价值分析*

王文轩, 李杰, 王馨蕊, 曹澍, 吴迪   

  1. 130031 吉林省长春市 解放军联勤保障部队第964医院放射诊断科(王文轩,曹澍);陆军军医大学大坪医院肝胆外科(李杰);北部战区总医院放射诊断科(吴迪,王馨蕊)
  • 收稿日期:2025-11-17 发布日期:2026-09-14
  • 通讯作者: 吴迪,E-mail:lanyang369@163.com
  • 作者简介:王文轩,男,39岁,医学硕士,副主任医师。E-mail:19904413208@163.com
  • 基金资助:
    辽宁省科技厅科学技术研究计划项目(编号:2025-MS-351)

Classification of cholangiocarcinoma staging by CT and MRI enhanced scans

Wang Wenxuan, Li Jie, Wang Xinrui, et al   

  1. Department of Radiology, 964th Hospital, Joint Logistics Support Force, Changchun 130031, Jilin Province,China
  • Received:2025-11-17 Published:2026-09-14

摘要: 目的 分析计算机断层成像(CT)与磁共振成像(MRI)增强扫描和磁共振胰胆管成像(MRCP)技术评估胆管癌(CC)患者临床分期的诊断价值。方法 2023年10月~2025年6月我院收治的61例CC患者,均接受CT、MRI增强扫描和MRCP检查。以组织病理学检查诊断为金标准,应用Kappa检验分析CT和MRI检查诊断的一致性。结果 在61例CC患者中,病理学检查诊断临床分期Ⅰ期10例,Ⅱ期15例,Ⅲ期19例和Ⅳ期17例; CT、MRI增强和MRCP联合检查诊断CC临床Ⅱ期的准确率为93.3%,显著高于CT检查的53.3%(P<0.05);联合诊断临床Ⅲ期的准确率为94.7%,显著高于CT、MRI增强或MRCP单独检查(分别为63.2%、68.4%和63.2%,P<0.05);联合诊断临床Ⅳ期的准确率为94.1%,显著高于CT、MRI增强或MRCP单独检查(分别为52.9%、64.7%和58.8%,P<0.05);在本研究41例肝门部胆管癌患者中,MRCP对Bismuth-CorletteⅠ型、Ⅱ型、Ⅲa型、Ⅲb型和Ⅳ型诊断的准确率为70.7%(29/41)。结论 应用CT联合MRI和MRCP诊断CC患者临床分期的效能较高,可为CC术前精准分期、手术可切除性判断和个体化治疗方案的制定提供影像学依据。

关键词: 胆管癌, 临床分期, 计算机断层扫描, 磁共振增强成像, 磁共振胰胆管成像, 诊断

Abstract: Objective The aim of this study was to investigate diagnostic efficacy of computed tomography (CT) and magnetic resonance imaging (MRI) enhanced scans, including magnetic resonance cholangiopancreatography (MRCP), in clinical staging of patients with cholangiocarcinoma (CC). Methods 61 patients with CC were encountered in our hospital between October 2023 and June 2025, and they all received enhanced CT, MRI and MRCP examination before surgery. The diagnosis and tumor staging were proven by histopathological study. Diagnostic consistence was analyzed by Kappa. Results Of the 61 patients with CC, liver histopathological examination found clinical stage Ⅰ in 10 cases, stage Ⅱ in 15 cases, stage Ⅲ in 19 cases and stage Ⅳ in 17 cases; accuracy rate of CT combined with MRI and MRCP in the diagnosis of clinical stage II was 93.3%, much higher than 53.3%(P<0.05) by CT scan; accuracy rate of the three combination in the diagnosis of clinical stage Ⅲ was 94.7%, much higher than 63.2%, 68.4% and 63.2% (P<0.05) by CT, or MRI or MRCP alone; accuracy rate of the three combination in the diagnosis of clinical stage Ⅳ was 94.1%, much higher than 52.9%, 64.7% and 58.8% (P<0.05) by CT, or MRI or MRCP alone; of 41 patients with hilar CC, accuracy of MRCP in diagnosis of Bismuth-Corlette Ⅰ, Ⅱ, Ⅲa, Ⅲb and Ⅳ was 70.7%(29/41). Conclusion Clinical staging of patients with CC by enhanced CT, MRI and MRCP combination has a high diagnostic performance, which could provide a imaging basis for preoperative accurate tumor staging, surgical resectability assessment and individualized treatment strategy.

Key words: Cholangiocarcinoma, Clinical staging, Computed tomography, Enhanced magnetic resonance imaging, Magnetic resonance cholangiopancreatography, Diagnosis